Results 31 to 40 of about 34,847 (196)

The Synergistic Effects of the Glutathione Precursor, NAC and First-Line Antibiotics in the Granulomatous Response Against Mycobacterium tuberculosis

Frontiers in Immunology, 2018
Mycobacterium tuberculosis (M. tb), the causative bacterial agent responsible for tuberculosis (TB) continues to afflict millions of people worldwide. Although the human immune system plays a critical role in containing M.
Garrett Teskey, Ruoqiong Cao, Ruoqiong Cao, Hicret Islamoglu, Albert Medina, Chaya Prasad, Ramaa Prasad, Airani Sathananthan, Marcel Fraix, Selvakumar Subbian, Li Zhong, Li Zhong, Li Zhong, Vishwanath Venketaraman, Vishwanath Venketaraman   +14 more
doaj   +1 more source

Attenuation of Mycobacterium species through direct and macrophage mediated pathway by unsymmetrical diaryl urea [PDF]

, 2016
Tuberculosis is a major threat for mankind and the emergence of resistance strain of Mycobacterium tuberculosis (Mtb) against first line antibiotics makes it lethal for human civilization.
Charan Raja, Mamilla R., Datta, Dhrubajyoti, Debnath, Joy, Franzblau, Scott G., Gramajo, Hugo Cesar, Halloum, Iman, Kar Mahapatra, Santanu, Kremer, Laurent, Tsai, Yi Ting, Velappan, Anand Babu, Wan, Baojie   +10 more
core   +1 more source

Mechanochemical Synthesis and Physicochemical Characterization of Isoniazid and Pyrazinamide Co-crystals With Glutaric Acid

Frontiers in Chemistry, 2020
The present work reports two novel pharmaceutical co-crystals; 2:1 isoniazid-glutaric acid (INHGA) and 2:1 pyrazinamide-glutaric acid (PGA). Isoniazid and pyrazinamide are key first-line drugs used for the treatment of tuberculosis.
Jean Baptiste Ngilirabanga, Marique Aucamp, Paulo Pires Rosa, Halima Samsodien   +3 more
doaj   +1 more source

Dual Antitubercular and Antileishmanial Profiles of Quinoxaline Di-N-Oxides Containing an Amino Acidic Side Chain

Pharmaceuticals
We present a new category of quinoxaline di-N-oxides (QdNOs) containing amino acid side chains with dual antituberculosis and antileishmanial activity.
Juan F. González, María-Auxiliadora Dea-Ayuela, Lena Huck, José María Orduña, Francisco Bolás-Fernández, Elena de la Cuesta, Nazia Haseen, Ashraf Ali Mohammed, J. Carlos Menéndez   +8 more
doaj   +1 more source

Synthesis, biological evaluation, and SAR study of novel pyrazole analogues as inhibitors of Mycobacterium tuberculosis: Part 2. Synthesis of rigid pyrazolones [PDF]

, 2009
Two series of novel rigid pyrazolone derivatives were synthesized and evaluated as inhibitors of Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis. Two of these compounds showed a high activity against MTB (MIC = 4 μg/mL).
Alessandro De Logu, Beatrice Bechi, Biava, Biava, Biava, Brock, Castagnolo, Daniele Castagnolo, De Logu, Deidda, Fabrizio Manetti, Gutierrez-Lugo, Holzer, Janin, Mafalda Pagano, Manetti, Manuela Saddi, Marco Radi, Maurizio Botta, Rita Meleddu   +19 more
core   +1 more source

Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay [PDF]

, 2013
Objectives: Lead antituberculosis (anti-TB) molecules with novel mechanisms of action are urgently required to fuel the anti-TB drug discovery pipeline.
Bhakta, Sanjib, Birchall, K., Evangelopoulos, Dimitrios, Gibbons, S., Gupta, Antima, Guzman, Juan D., Malkinson, J., McHugh, T.D., Mwaigwisya, S., Saxty, B.   +9 more
core   +1 more source

Synergistic Lethality of a Binary Inhibitor of Mycobacterium tuberculosis KasA

mBio, 2018
We report GSK3011724A (DG167) as a binary inhibitor of β-ketoacyl-ACP synthase (KasA) in Mycobacterium tuberculosis. Genetic and biochemical studies established KasA as the primary target.
Pradeep Kumar, Glenn C. Capodagli, Divya Awasthi, Riju Shrestha, Karishma Maharaja, Paridhi Sukheja, Shao-Gang Li, Daigo Inoyama, Matthew Zimmerman, Hsin Pin Ho Liang, Jansy Sarathy, Marizel Mina, George Rasic, Riccardo Russo, Alexander L. Perryman, Todd Richmann, Aditi Gupta, Eric Singleton, Sheetal Verma, Seema Husain, Patricia Soteropoulos, Zhe Wang, Roxanne Morris, Gene Porter, Gautam Agnihotri, Padmini Salgame, Sean Ekins, Kyu Y. Rhee, Nancy Connell, Véronique Dartois, Matthew B. Neiditch, Joel S. Freundlich, David Alland   +32 more
doaj   +1 more source

Cutaneous drug reaction secondary to antitubercular regimen: A case report from Nepal

SAGE Open Medical Case Reports, 2023
Cutaneous adverse drug reactions are known side effects of first-line antitubercular therapy, which ranges from mild pruritus to life-threatening toxic epidermal necrolysis.
Himal Bikram Bhattarai, Jeshika Yadav, Sangrila Sapkota, Adarsha Adhikari, Madhur Bhattarai, Ishani Singh, Sujan Shrestha, Jwala KC, Prakash Karki, Bibhusan Basnet   +9 more
doaj   +1 more source

Promising Lead Compounds in the Development of Potential Clinical Drug Candidate for Drug-Resistant Tuberculosis

Molecules, 2020
According to WHO report, globally about 10 million active tuberculosis cases, resulting in about 1.6 million deaths, further aggravated by drug-resistant tuberculosis and/or comorbidities with HIV and diabetes are present. Incomplete therapeutic regimen,
Saad Alghamdi, Shaheed Ur Rehman, Nashwa Talaat Shesha, Hani Faidah, Muhammad Khurram, Sabi Ur Rehman   +5 more
doaj   +1 more source

Cutaneous tuberculosis (scrofuloderma) in a five year-old boy: Case report [PDF]

, 2009
Cutaneous tuberculosis (CTB) is a rare form of extrapulmonary TB in our region. The incidence of CTB seems to be increasing in some countries. CTB continues to be one of the most elusive and difficult diagnoses to make for dermatologists practicing in ...
Dehghan, M., Kazeminezhad, V., Najafi, L.   +2 more
core